The Accuracy of TIAC Calculated Using SPECT/CT Imaging Data at 36- and 100-Hours Post Injection and Prior Information in 177Lu-DOTATATE
DOI:
https://doi.org/10.25077/jif.16.1.55-62.2024Keywords:
Absorbed dose, Bayesian, TIAC, SPECT-CT, 177Lu-DOTATATEAbstract
In internal radionuclide therapy, there is a growing demand for streamlined methods that alleviate the measurement burden on patients and reduce the associated costs of individual dosimetry. This study assessed the precision of the Two Time Point Dosimetry (2TPD) model, a data-efficient approach, compared to the well-established All Time Point Dosimetry (ATPD) model. The investigation involved the analysis of time-activity data collected from the kidneys of seven patients who were administered 177Lu-DOTATATE and underwent SPECT/CT imaging (PMID 3344306). Data points were specifically gathered at the 36-hour and 100-hour post-injection marks. Employing prior information, a monoexponential function was applied to fit the biokinetic data. Consequently, two crucial metrics, TIAC ATPD and TIAC 2TPD, were computed for ATPD and 2TPD, respectively. To provide a benchmark, the TIAC determined via the Hänscheid method was also incorporated for comparison. The comparative analysis revealed that the percentage error between the population ATPD model and the 2TPD model was (3.97 ± 7.85)%, and for the Hänscheid model, it was (1.8 ± 7.9)%. These findings affirm that the accuracy of TIAC values derived from the 2TPD approach, leveraging prior-information fitting, is reasonably satisfactory.
Downloads
References
Bergsma, H., Konijnenberg, M. W., van der Zwan, W. A., Kam, B. L. R., Teunissen, J. J. M., Kooij, P. P., Mauff, K. A. L., Krenning, E. P., & Kwekkeboom, D. J. (2016). Nephrotoxicity after PRRT with 177 Lu-DOTA-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 43, 1802–1811.
Bolch, W. E., Eckerman, K. F., Sgouros, G., & Thomas, S. R. (2009). MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature. Journal of Nuclear Medicine, 50(3), 477–484.
Cherry, S. R., Sorenson, J. A., & Phelps, M. E. (2012). Physics in nuclear medicine e-Book. Elsevier Health Sciences.
Devasia, T. P., Dewaraja, Y. K., Frey, K. A., Wong, K. K., & Schipper, M. J. (2021). A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 62(8), 1118–1125. https://doi.org/10.2967/jnumed.120.256255
Gear, J. I., Cox, M. G., Gustafsson, J., Gleisner, K. S., Murray, I., Glatting, G., Konijnenberg, M., & Flux, G. D. (2018). EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2456–2474.
Glatting, G., Bardiès, M., & Lassmann, M. (2013). Treatment planning in molecular radiotherapy. Zeitschrift Für Medizinische Physik, 23(4), 262–269.
Glatting, G., Kletting, P., Reske, S. N., Hohl, K., & Ring, C. (2007). Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test. Medical Physics, 34(11), 4285–4292. https://doi.org/10.1118/1.2794176
Gustafsson, J., & Taprogge, J. (2022). Theoretical aspects on the use of single-time-point dosimetry for radionuclide therapy. Physics in Medicine & Biology, 67(2), 25003.
Hänscheid, H., Lapa, C., Buck, A. K., Lassmann, M., & Werner, R. A. (2018). Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days. Journal of Nuclear Medicine, 59(1), 75–81.
Hardiansyah, D., Maass, C., Attarwala, A. A., Müller, B., Kletting, P., Mottaghy, F. M., & Glatting, G. (2016). The role of patient-based treatment planning in peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 43(5), 871–880.
Haug, A. R. (2020). PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Research, 10(1), 1–3.
Hou, X., Brosch, J., Uribe, C., Desy, A., Böning, G., Beauregard, J.-M., Celler, A., & Rahmim, A. (2021). Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. Journal of Nuclear Medicine, 62(7), 1006–1011.
Jiménez-Franco, L. D., Glatting, G., Prasad, V., Weber, W. A., Beer, A. J., & Kletting, P. (2021). Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment. Journal of Nuclear Medicine, 62(1), 92–98. https://doi.org/10.2967/jnumed.120.245068
Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., Van Vliet, E. I., & Kwekkeboom, D. J. (2012). Lutetium-labelled peptides for therapy of neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 39(1), 103–112.
Kletting, P., Schimmel, S., Kestler, H. A., Hänscheid, H., Luster, M., Fernandez, M., Bröer, J. H., Nosske, D., Lassmann, M., & Glatting, G. (2013). Molecular radiotherapy: the NUKFIT software for calculating the time‐integrated activity coefficient. Medical Physics, 40(10), 102504.
Maaß, C., Sachs, J. P., Hardiansyah, D., Mottaghy, F. M., Kletting, P., & Glatting, G. (2016). Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule. EJNMMI Research, 6(1), 1–9.
Miederer, M., Reber, H., Helisch, A., Fottner, C., Weber, M., & Schreckenberger, M. (2012). One single-time-point kidney uptake from OctreoScan correlates with number of desintegrations measured over 72 hours and calculated for the 6.7 hours half-life nuclide 177Lu. Clinical Nuclear Medicine, 37(10), e245–e248.
Siegel, J. A., Thomas, S. R., Stubbs, J. B., Stabin, M. G., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., & Fisher, D. R. (1999). MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. Journal of Nuclear Medicine, 40(2), 37S-61S.
Thundimadathil, J. (2012). Cancer treatment using peptides: current therapies and future prospects. Journal of Amino Acids, 2012:967347. doi: 10.1155/2012/967347.
Vicini, P., Brill, A. B., Stabin, M. G., & Rescigno, A. (2008). Kinetic modeling in support of radionuclide dose assessment. Seminars in Nuclear Medicine, 38(5), 335–346. https://doi.org/10.1053/j.semnuclmed.2008.05.007
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2023 Rizka Mutik Siyami, Sri Oktamuliani, M. Dlorifun Naqiyyun, Intan Apriliani Syaridatul Mu'minah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Please find the rights and licenses in JIF (Jurnal Ilmu Fisika).
1. License
The non-commercial use of the article will be governed by the Creative Commons Attribution license as currently displayed on Creative Commons Attribution-NonCommercial 4.0 International License.
2. Author's Warranties
The author warrants that the article is original, written by stated author(s), has not been published before, contains no unlawful statements, does not infringe the rights of others, is subject to copyright that is vested exclusively in the author and free of any third party rights, and that any necessary written permissions to quote from other sources have been obtained by the author(s).
3. User Rights
JIF's spirit is to disseminate articles published are as free as possible. Under the Creative Commons license, JIF permits users to copy, distribute, display, and perform the work for non-commercial purposes only. Users will also need to attribute authors and JIF on distributing works in the journal.
4. Rights of Authors
Authors retain the following rights:
- Copyright, and other proprietary rights relating to the article, such as patent rights,
- The right to use the substance of the article in future own works, including lectures and books,
- The right to reproduce the article for own purposes, provided the copies are not offered for sale,
- The right to self-archive the article.
5. Co-Authorship
If the article was jointly prepared by other authors, the signatory of this form warrants that he/she has been authorized by all co-authors to sign this agreement on their behalf, and agrees to inform his/her co-authors of the terms of this agreement.
6. Termination
This agreement can be terminated by the author or JIF upon two months's notice where the other party has materially breached this agreement and failed to remedy such breach within a month of being given the terminating party's notice requesting such breach to be remedied. No breach or violation of this agreement will cause this agreement or any license granted in it to terminate automatically or affect the definition of JIF.
7. Royalties
This agreement entitles the author to no royalties or other fees. To such extent as legally permissible, the author waives his or her right to collect royalties relative to the article in respect of any use of the article by JIF or its sublicensee.
8. Miscellaneous
JIF will publish the article (or have it published) in the journal if the article's editorial process is successfully completed and JIF or its sublicensee has become obligated to have the article published. JIF may conform the article to a style of punctuation, spelling, capitalization, referencing and usage that it deems appropriate. The author acknowledges that the article may be published so that it will be publicly accessible and such access will be free of charge for the readers.
